You are here

ALKS 3831

Alkermes sees swift turnaround for rejected schizophrenia med as FDA accepts resubmission

Fierce Biotech

Tue, 12/29/20 - 10:51 am

drug manufacturing

Drug rejections rise as Covid-19 bites

EP Vantage

Wed, 11/18/20 - 01:20 pm

regulatory inspections

FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats

Xconomy

Sat, 10/10/20 - 11:36 pm

advisory panels

bipolar disorder

FDA Raises Concern Over Opioid Abuse Related to Alkermes' Schizophrenia Drug

BioSpace

Thu, 10/8/20 - 11:21 pm

Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on drug-drug interactions

Fierce Biotech

Fri, 08/21/20 - 11:36 pm

bipolar disorder

A double date with destiny for Alkermes

EP Vantage

Fri, 10/5/18 - 12:06 pm

clinical trials

Alkermes says it's advancing 'full steam' with schizophrenia candidate

Fierce Biotech

Sat, 07/1/17 - 09:28 am

Side Effect Weighs on Early Results for Alkermes’ Schizophrenia Drug

Xconomy

Fri, 06/30/17 - 09:40 am

clinical trials

Alkermes claims a success in PhIII schizophrenia head-to-head, but where’s the benefit for patients?

Endpoints

Thu, 06/29/17 - 09:41 pm

clinical trials

Alkermes heads to Phase III with a schizophrenia drug designed to spare the waistline

Fierce Biotech

Mon, 04/6/15 - 11:45 am

Alkermes sees PhII promise for schizophrenia drug that doesn't pack on pounds

Fierce Biotech

Wed, 01/7/15 - 09:21 am

Alkermes Completes Enrolment for Phase II ALKS 3831 Study

Yahoo/Zacks.com

Fri, 09/5/14 - 07:57 am

Alkermes' Pipeline Development Impresses, Key Updates Ahead

Yahoo/Reuters

Tue, 07/22/14 - 08:54 am

Invega Sustenna

aripiprazole lauroxil